Delphine Topart

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2021 · 746 citations · Full text

Medicine, Oncology, Pharmacotherapy +13

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Frequent expression of PD‐L1 on circulating breast cancer cells

Martine Mazel, William Jacot, Klaus Pantel et al. · Molecular Oncology · 2015 · 369 citations · Full text

Medicine, Cancer Biology, Oncology +17

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park et al. · New England Journal of Medicine · 2024 · 285 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 278 citations · Full text

Medicine, Oncology, Pharmacotherapy +16